JPB898
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for JPB898, covering 2026-02-24 to 2026-02-24. Get the full timeline:
Most recent: Clinical Trial Update: Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy® [Phase 3]